Notwithstanding anti-vascular endothelial growth factor (VEGF) [3,4] and anti-epidermal growth factor receptor (EGFR) therapies [5,6], two targeted treatments currently available for CRC, relatively few means of improving survival have been reported. The gene discussed is VEGFA; the disease is colorectal carcinoma.